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INVITED COMMENTS
Regarding “High embolic rate early after carotid
endarterectomy is associated with early
cerebrovascular complications, especially
in women”
A. Ross Naylor, MD, FRCS, Leicester, United Kingdom
Postoperative carotid thrombosis (POCT) complicates
2% to 3% of carotid endarterectomies (CEAs) and classically
occurs 4 to 6 hours after restoration of flow. It was previ-
ously held that POCT was almost invariably associated with
some underlying technical error and incurred a poor out-
come unless thrombectomy was performed within 1 hour.
Viewed traditionally as being unpreventable, it would
clearly be preferable to identify patients at high risk early
and so intervene (therapeutically or surgically) to prevent
progression onto thrombosis and stroke. The paper by
Laman et al, in this edition of the Journal, is now the latest
of five around the world1-6 to suggest that many of the
traditionally held views regarding POCT need revising and
that transcranial Doppler (TCD)–directed embolus moni-
toring may be invaluable in identifying those at highest risk.
The available evidence suggests that a policy of quality
control assessment will virtually abolish intraoperative
stroke (apparent on recovery from anesthesia) but that this
will have surprisingly little effect on the rate of stroke as the
result of POCT.7 Secondly, provided technical error has
been excluded with some form of completion assessment
(eg, angioscopy), patients who subsequently have a stroke
because of POCT are unlikely to have underlying technical
error at reexploration.3 Interestingly, most are found to
have platelet-rich thrombus that is adherent to the endar-
terectomy zone rather than to the patch. It is now well
accepted that platelets begin to adhere to the endarterec-
tomy zone within minutes of flow restoration,8 but no one
knows why it becomes excessive in certain patients. Thirdly,
there are now five studies (including that of Laman et al)
that suggest that patients destined to progress to stroke
because of POCT have a 1-hour to 2-hour period of
increasing embolization before any neurologic deficit be-
comes apparent.1-6 The prevailing view is that, as the
platelet thrombus accumulates, small particles are increas-
ingly shed into the carotid circulation and detected with the
TCD. Overall, about 50% of patients with CEA will have
one or more emboli detected in the postoperative period,
but only about 5% will progress to high-grade sustained
embolization.7 In Laman et al’s series, 30% of these patients
with high embolization progressed to stroke, increasing to
50% in the Leicester series3 and 60% in Levi et al’s4 Austra-
lian study.
Unfortunately, because of methodologic differences
among the five studies (varying monitoring times [10 to
180 minutes], divergent antiplatelet and reexploration pol-
icies [especially in Laman et al’s study] and differing policies
regarding intervention [Boston gave dextran to all patients
with CEA, Leicester administered dextran 40 to all patients
with high-rate embolization]), it is currently impossible to
combine the data and present an overview of the principal
findings. This problem may, however, be resolved in the
future when a collaboration of interested researchers rean-
alyze all of the raw data from the various major studies.
Laman et al’s study proposes that an embolus rate of
0.9/min represents a threshold for increased risk, and in
Leicester, we would only intervene if the embolus count
exceeded 25 in any 10-minute monitoring period (2.5
emboli/min) or where the embolus distorted the waveform
suggesting that it was large.7 Our threshold of 25 in 10
minutes was based on Gaunt et al’s original work.3 To date,
we have not observed any early embolic stroke in anyone
with an embolus rate of between 0.9/min and 2.5/min,
which is clearly at variance with Laman et al’s findings,
although part of the discrepancy might be explained by our
use of completion angioscopy and the substitution of aspi-
rin with warfarin 1 week before surgery in the Dutch center.
However, despite the methodologic problems, these
five studies should now be the catalyst for studying the
phenomenon of POCT in a more standardized manner,
especially regarding antiplatelet regimes (see below). In
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particular, we do need to know: 1, whether other centers
have unpublished data on postoperative monitoring that
will further our knowledge; 2, whether certain people
appear to be at increased risk of POCT; and 3, what the best
treatment is for patients with high-grade embolization.
Contrary to traditional teaching, current research now
suggests that it is the patient who is probably prothrom-
botic. Patients at high risk might therefore be identified
before surgery in the future. Evidence supporting this
hypothesis includes the following observations: 1, postop-
erative embolization is unrelated to patch type (prosthetic
versus vein9); 2, patients undergoing staged bilateral CEAs
have similar magnitudes of embolization after each proce-
dure10 (if the patient had a high embolization after the first
CEA, the same is likely after the second); and 3, the
magnitude of embolization is unrelated to aspirin therapy,
but the platelets of patients with high rate embolization are
significantly more sensitive to adenosine diphosphate stim-
ulation.11 In addition, Laman et al’s observation that fe-
male patients have a higher rate of postoperative emboliza-
tion (than male patients) is important and could explain
why women traditionally have a higher operative stroke rate
than men.
There is also no current consensus as to the best way of
treating patients at high risk for POCT. A number of
options are available including: 1, routine intravenous dex-
tran 40 therapy5; 2, selective dextran 40 therapy to patients
with high-rate embolization7; 3, intravenous S-nitrosoglu-
tathione12; 4, intravenous rheopro; or 5, intravenous hep-
arin (as was used in Laman et al’s study).
The disadvantage of routine dextran is that up to 36%
of patients with high-rate embolization need an increase in
the dose to control the excessive rates of embolization.7
Despite administering routine dextran to their patients
with CEA after restoration of flow, up to 20% of the Boston
patients still had one or more emboli detected after surgery
and POCT was still observed.5 Of more practical impor-
tance, dextran should not be administered to patients with
significant chronic renal impairment because of risk of
precipitating multiorgan failure. We have observed a major
change in surgical practice since we introduced a program
of 3-hour TCD monitoring and selective dextran 40 ther-
apy in October 1995. Since then, dextran has only been
administered to 4% of patients and 850 CEAs have been
performed. No one during this time has had a stroke as a
result of POCT. On the basis of previous experience, we
might otherwise have expected to have reexplored 17 to 25
patients for postoperative thrombotic stroke.
In conclusion, despite many false dawns, TCD appears
at last to have found a valuable role in the prediction and
prevention of POCT. Although some centers may wish to
use TCD to identify patients at high risk in the early
postoperative period, it seems likely that the optimal role
for TCD in the future will be to enable clinicians to develop
novel antiplatelet strategies (preferably administered before
surgery) so that, ultimately, no postoperative monitoring is
necessary at all.
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